Business Description
Traws Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US68232V3069
Description
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.47 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -31.01 | |||||
| Beneish M-Score | -3.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -18.1 | |||||
| 3-Year EBITDA Growth Rate | 23.4 | |||||
| 3-Year EPS without NRI Growth Rate | 25.3 | |||||
| 3-Year FCF Growth Rate | 24.5 | |||||
| 3-Year Book Growth Rate | 0.7 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.08 | |||||
| 9-Day RSI | 36.55 | |||||
| 14-Day RSI | 41.16 | |||||
| 6-1 Month Momentum % | 31.36 | |||||
| 12-1 Month Momentum % | -30.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.46 | |||||
| Quick Ratio | 2.46 | |||||
| Cash Ratio | 2.26 | |||||
| Days Sales Outstanding | 31.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -8981.42 | |||||
| Net Margin % | -8384.07 | |||||
| FCF Margin % | -7959.81 | |||||
| ROE % | -99.44 | |||||
| ROA % | -61.27 | |||||
| ROIC % | -1772.13 | |||||
| ROC (Joel Greenblatt) % | -92263.64 | |||||
| ROCE % | -92.44 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 53.45 | |||||
| PB Ratio | 1.26 | |||||
| Price-to-Tangible-Book | 1.22 | |||||
| EV-to-EBIT | 0.24 | |||||
| EV-to-EBITDA | 0.24 | |||||
| EV-to-Revenue | -21.32 | |||||
| EV-to-FCF | 0.26 | |||||
| Price-to-Median-PS-Value | 2.21 | |||||
| Price-to-Net-Current-Asset-Value | 1.22 | |||||
| Price-to-Net-Cash | 1.51 | |||||
| Earnings Yield (Greenblatt) % | 414.4 | |||||
| FCF Yield % | -112.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Traws Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.209 | ||
| EPS (TTM) (€) | -0.846 | ||
| Beta | 1.59 | ||
| Volatility % | 66.48 | ||
| 14-Day RSI | 41.16 | ||
| 14-Day ATR (€) | 0.06327 | ||
| 20-Day SMA (€) | 0.7425 | ||
| 12-1 Month Momentum % | -30.8 | ||
| 52-Week Range (€) | 0.545 - 1.68 | ||
| Shares Outstanding (Mil) | 25.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Traws Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Traws Pharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Traws Pharma Inc Frequently Asked Questions
What is Traws Pharma Inc(STU:0T2)'s stock price today?
The current price of STU:0T2 is €0.57. The 52 week high of STU:0T2 is €1.68 and 52 week low is €0.55.
When is next earnings date of Traws Pharma Inc(STU:0T2)?
The next earnings date of Traws Pharma Inc(STU:0T2) is 2024-05-15 Est..
Does Traws Pharma Inc(STU:0T2) pay dividends? If so, how much?
Traws Pharma Inc(STU:0T2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers